Editor’s introduction to the initial issue of the fourth volume of GaBI Journal
Biosimilars: patient and physician acceptability is the fifth hurdle to market competition
Generic medicines policy in Qatar
The EU regulatory approach to generics and biosimilars is essentially similar
The refinement of the super generic concept: semantic challenge for product re-innovation?
Top developments in biosimilars during 2014
Generics and off-patent biologicals for cancer treatment in developing countries
Source URL: https://gabi-journal.net/20151-gabi-journal-table-of-contents.html
Copyright ©2024 GaBI Journal unless otherwise noted.